1-5 of 5
Jonathan How
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Age ≥60 Is an Added Risk Factor for Mortality in High-Risk HCT-CI Patients Undergoing Allogeneic Stem Cell Transplant

Veronica Ramirez, Gizelle Popradi, John M. Storring, Jonathan How
Journal: Blood
Blood (2024) 144 (Supplement 1): 7926.
https://doi.org/10.1182/blood-2024-204066
Published: 2024
Journal Articles

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Jia Li Liu, Nushin Sadeghi, Owen Luo, Jonathan How, John M. Storring, Gizelle Popradi
Journal: Blood
Blood (2024) 144 (Supplement 1): 6029.
https://doi.org/10.1182/blood-2024-198536
Published: 2024
Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How
Journal: Blood
Blood (2022) 140 (Supplement 1): 583–585.
https://doi.org/10.1182/blood-2022-157949
Published: 2022
Journal Articles

An Increased Number of Cybord Induction Cycles Does Not Increase Peri-Transplant Morbidity in Multiple Myeloma Patients

Mahmood Al-Abri, MD, Jonathan How
Journal: Blood
Blood (2018) 132 (Supplement 1): 2312.
https://doi.org/10.1182/blood-2018-99-114274
Published: 2018
Journal Articles

Cytarabine and Etoposide (CYVE) as First-Line Therapy for Primary Central Nervous System Lymphoma

Jonathan How, MD, Margaret Warner, MD, Chaim Shustik, MD, Pierre Laneuville, MD
Journal: Blood
Blood (2010) 116 (21): 4895.
https://doi.org/10.1182/blood.V116.21.4895.4895
Published: 2010